Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-5: Ceritinib vs Chemotherapy in ALK+ NSCLC
NCT01828112Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jun 2013; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01828112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01828112.